Comprehensive characterization of the Published Kinase Inhibitor Set - Wikidata - awgldk - TriplyDB

Comprehensive characterization of the Published Kinase Inhibitor Set

Comprehensive characterization of the Published Kinase Inhibitor Set

http://www.wikidata.org/entity/Q27702518

about

Using a Genetically Encoded Sensor to Identify Inhibitors of Toxoplasma gondii Ca2+ Signaling.Using Pharmacogenomic Databases for Discovering Patient-Target Genes and Small Molecule Candidates to Cancer Therapy Accelerating glioblastoma drug discovery: Convergence of patient-derived models, genome editing and phenotypic screening Applications of chemogenomic library screening in drug discovery miR-625-3p regulates oxaliplatin resistance by targeting MAP2K6-p38 signalling in human colorectal adenocarcinoma cells Trust, but Verify II: A Practical Guide to Chemogenomics Data Curation.Open PHACTS computational protocols for in silico target validation of cellular phenotypic screens: knowing the knowns.EGFR inhibitors identified as a potential treatment for chordoma in a focused compound screen.Identification of Highly Potent Protein Kinase C-Related Kinase 1 Inhibitors by Virtual Screening, Binding Free Energy Rescoring, and in vitro Testing.The Retinoid Agonist Tazarotene Promotes Angiogenesis and Wound Healing.Structure and inhibitor specificity of the PCTAIRE-family kinase CDK16.A Simple Method to Identify Kinases That Regulate Embryonic Stem Cell Pluripotency by High-throughput Inhibitor Screening.DREADDs for Neuroscientists.A screen for kinase inhibitors identifies antimicrobial imidazopyridine aminofurazans as specific inhibitors of the Listeria monocytogenes PASTA kinase PrkA.Progress towards a public chemogenomic set for protein kinases and a call for contributions.Novel application of the published kinase inhibitor set to identify therapeutic targets and pathways in triple negative breast cancer subtypes.High-throughput screening of a GlaxoSmithKline protein kinase inhibitor set identifies an inhibitor of human cytomegalovirus replication that prevents CREB and histone H3 post-translational modification.Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 - Part II.Non-kinase targets of protein kinase inhibitors.Remarkably Stereospecific Utilization of ATP α,β-Halomethylene Analogues by Protein Kinases.Prediction of intracellular exposure bridges the gap between target- and cell-based drug discovery.Structural characterization of human Vaccinia-Related Kinases (VRK) bound to small-molecule inhibitors identifies different P-loop conformations.Kinase inhibitor screening using artificial neural networks and engineered cardiac biowires Systematic Kinase Inhibitor Profiling Identifies CDK9 as a Synthetic Lethal Target in NUT Midline Carcinoma.How Ligands Illuminate GPCR Molecular Pharmacology.A Comprehensive Structural Overview of p38α Mitogen-Activated Protein Kinase in Complex with ATP-Site and Non-ATP-Site Binders.The target landscape of clinical kinase drugs.Tension Creates an Endoreplication Wavefront that Leads Regeneration of Epicardial Tissue.Quantitative, Wide-Spectrum Kinase Profiling in Live Cells for Assessing the Effect of Cellular ATP on Target Engagement.High-throughput screen for compounds that modulate neurite growth of human induced pluripotent stem cell derived neurons.Protocols for the Design of Kinase-Focused Compound Libraries.New chemical tools for probing activity and inhibition of the NAD+-dependent lysine deacylase sirtuin 2.New opportunities for kinase drug repurposing and target discovery.A generic HTS assay for kinase screening: Validation for the isolation of an engineered malate kinase.How to Achieve Better Results Using PASS-Based Virtual Screening: Case Study for Kinase Inhibitors.1,2,6-Thiadiazinones as Novel Narrow Spectrum Calcium/Calmodulin-Dependent Protein Kinase Kinase 2 (CaMKK2) Inhibitors.Immuno-detection by sequencing enables large-scale high-dimensional phenotyping in cells.Prediction of Compound Profiling Matrices Using Machine Learning.New tools for carbohydrate sulfation analysis: heparan sulfate 2--sulfotransferase (HS2ST) is a target for small-molecule protein kinase inhibitors Identification of lead anti-human cytomegalovirus compounds targeting MAP4K4 via machine learning analysis of kinase inhibitor screening data

P2860

Q27312141-9A1D74D8-79E6-4B72-BEF9-6C451DDD6176 Q28076097-2D049A6B-47EF-4B28-9531-D17099573E7A Q28080068-86698256-5C84-46C5-AF36-A89057E9C663 Q28656335-D573BCAF-C236-43D3-97F4-99D40F38A357 Q28829677-0493A617-D242-4148-9B59-1910554EE2A3 Q31106801-95574FCD-A391-4CC2-BB18-E8D565711A16 Q31202630-AA6F7173-7897-4B0C-9793-B988D371FD37 Q33276007-578848F2-1F57-4479-8493-3E7DA1922503 Q36089876-1E6E75E6-1D59-4C1E-8021-96AAFCBA9BD1 Q36092050-D43C1A63-6351-4107-ADCE-B55AABCB9E05 Q36241608-2C85D8BE-8582-4646-8A69-F25D0E46A5F8 Q36389300-CE4B4773-0DE0-4E58-8975-22C9B4DC94AD Q36595793-75EB9866-A4CF-4CA4-A3C5-F6982B7B47C4 Q38618015-A46B7D2C-D9F3-4206-8CEC-B1DE3B7BF1E0 Q38646648-3258B5B3-FFC8-4E38-A216-B45036AE84E2 Q38647605-7BFA9A52-CDFA-428B-849A-9951996B2916 Q39013996-9EED8F0D-EDDD-497B-AF94-2A7C342ED273 Q39166808-EC255E2E-0F70-48EE-B311-5BF2962AB10D Q39171961-9E8884D5-80FB-4F05-8346-903140BDC4D6 Q40189472-BF2E7C0A-5180-43DB-90AB-6239F0920D0B Q41256404-13851BCB-FE18-4EB0-8FCA-6D8C55D4FA5B Q41309405-77AC5446-E290-4504-ADDF-CBDE82D7BEDA Q41718114-B3F87F5B-C363-4AD3-AD28-9C70139683B6 Q42367759-5D4C79DE-1FD3-4A9E-8831-11F676FB958A Q43757698-9720504A-95CD-467C-B110-9D709D8FEDEE Q47324721-909C9ACC-81A1-4875-A2EC-A81A9EC77B48 Q47345032-05EA0883-6ACB-4133-9E51-3BDC931304D1 Q47630488-03BAE5B6-0B72-4888-AC9F-C6507B7EE389 Q47700032-80946A33-F96D-4E56-843D-E33796817EC0 Q48183777-8CDC1924-C321-4EF0-853F-CE6B706CB38C Q50107785-C328F80F-D445-418C-939F-9CB8FCE214E6 Q52568734-75D7041E-566F-4E79-BDFB-CB5BE70362BC Q52653202-6CF7B3B2-AD94-4ADD-9938-618C2E8916D1 Q52692666-850E6F49-1D33-40E1-AA13-2A2EB9DAD20F Q54110122-49C61E5A-402B-474A-A510-D4769C4732B4 Q54978646-EBDD9584-9DBE-49F9-9900-BF62BE664148 Q55188599-BE43FBDE-6617-4586-ACB5-C8249592FEC8 Q55691676-7503C7A0-8978-4288-AC5A-C327FBC3B884 Q56833662-D098E729-154F-4264-A78B-0C0FDA759E85 Q56889371-C4B0AC91-B2EB-4D37-A5F1-730D91F5C510

P2860

Comprehensive characterization of the Published Kinase Inhibitor Set

http://www.wikidata.org/entity/Q27702518

description

2016 nî lūn-bûn

@nan

2016 թուականի Յունուարին հրատարակուած գիտական յօդուած

@hyw

2016 թվականի հունվարին հրատարակված գիտական հոդված

@hy

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

name

Comprehensive characterization of the Published Kinase Inhibitor Set

@ast

Comprehensive characterization of the Published Kinase Inhibitor Set

@en

Comprehensive characterization of the Published Kinase Inhibitor Set

@nl

type

label

Comprehensive characterization of the Published Kinase Inhibitor Set

@ast

Comprehensive characterization of the Published Kinase Inhibitor Set

@en

Comprehensive characterization of the Published Kinase Inhibitor Set

@nl

prefLabel

Comprehensive characterization of the Published Kinase Inhibitor Set

@ast

Comprehensive characterization of the Published Kinase Inhibitor Set

@en

Comprehensive characterization of the Published Kinase Inhibitor Set

@nl

P1433

Q27702518-B04EE76A-2B31-4532-A327-1A35742D898E

P1476

Q27702518-335FA2F1-B2EC-4A3A-B493-4B9150A34A1C

P2093

Q27702518-0286B5C1-71A8-4DC3-A686-DED42CEF0696

Q27702518-15F2115B-5DF6-417D-AAE0-216DFB15711C

Q27702518-1E15F461-0758-4551-981D-6F8D3DBA8390

Q27702518-1ED76A67-8F2A-4800-8CC8-3183EEBBE291

Q27702518-25607002-078B-4E2F-AA51-45BDA7E071DE

Q27702518-5FAA6CBA-DA29-4FB0-B62A-C5113CCF8D83

Q27702518-68AAB7E4-09E1-4C7A-881D-9C903DACFD4A

Q27702518-6BA23BC2-DD65-42D8-B83C-7026BD38133C

Q27702518-8529EE60-0B0C-4B9C-9C48-17507C861DA2

Q27702518-92526157-ABBD-4391-A35C-40C06371C399

P2860

Q27702518-21B19AA4-E8F9-4D69-A06B-DA277126F023

Q27702518-26C80841-239D-4279-B03E-676CB0C1EE65

Q27702518-2F71348F-96E9-4C46-92BE-D6BD40890339

Q27702518-4191594A-792E-45A6-A101-A479D37B8D46

Q27702518-4F4BA10D-5B4C-4BB9-864F-BE32A1209C23

Q27702518-5E6F900E-BFAA-4268-A3EA-65CC2E67F0A7

Q27702518-74E43A46-E002-403C-BF3E-5EE9D350131B

Q27702518-8078853B-1C9F-4B0D-8293-1DF0538042B7

Q27702518-95D75F0F-4F64-4539-8EFD-8585B1C131A7

Q27702518-9DF4CD69-142E-4410-BE78-DF8978EF5E18

P2888

Q27702518-0A1311B8-F9C1-4FF8-B799-6ACC8C9CF035

P304

Q27702518-DA7868F3-F56A-4576-8C7B-C5F8BF88C03E

P31

Q27702518-3C1CF758-5D2B-4656-9081-8DDE15555E5B

P3181

Q27702518-900EA26B-D2A7-4E8E-8CDD-2D3B2C4BC27C

P356

Q27702518-6C3AEA5F-BEFE-4B5A-9AF8-1B23ADC94DEF

P433

Q27702518-CAC29C34-C090-4329-B7E4-E0FB3BE387BB

P478

Q27702518-866475E0-48DE-471D-BD7F-433F9BF1A0B8

P50

Q27702518-15C08E5D-EFF3-4D12-8CF6-B4B1828FE02E

Q27702518-3272097C-A490-4982-B283-51E05C0E58C4

Q27702518-3F98B75B-B58C-4207-80A0-3CD5879345F0

Q27702518-5636E029-B420-47B8-8EE9-F9CD3F16EEB1

Q27702518-7AF135AF-9A45-4CED-9F62-54CB3EDF05CC

Q27702518-7C20168C-7012-4703-AD2F-8774B86E8B8D

Q27702518-A37BD929-A51D-4757-BAD3-FE5C67FA5A0D

Q27702518-B5363357-CB23-4C8C-88C1-B2EB490103AE

Q27702518-BD8BEAA7-3D76-48B3-9771-0FB619D96E9C

Q27702518-C0771CE2-F85C-4F81-9333-94E6EAA6CC93

P577

Q27702518-55992086-FF5F-453F-B84C-7E508CD7479A

P5875

Q27702518-D2E71B20-FC97-4360-BD1B-247DFFFE7660

P6179

Q27702518-E293E3FC-40FD-4BB1-B422-C543F31BD1AC

P698

Q27702518-00213B90-E030-401B-9A96-C3CE50F78B1B

P3181

P356

P1433

Nature Biotechnology

P1476

Comprehensive characterization of the Published Kinase Inhibitor Set

@en

P2093

Alex Tropsha

http://www.w3.org/2001/XMLSchema#string

Beverly A Teicher

http://www.w3.org/2001/XMLSchema#string

Bryan L Roth

http://www.w3.org/2001/XMLSchema#string

Daniel J Price

http://www.w3.org/2001/XMLSchema#string

Eric Polley

http://www.w3.org/2001/XMLSchema#string

Joel Morris

http://www.w3.org/2001/XMLSchema#string

Jowita Mikolajczyk

http://www.w3.org/2001/XMLSchema#string

Kamal R Abdul Azeez

http://www.w3.org/2001/XMLSchema#string

Karen E Lackey

http://www.w3.org/2001/XMLSchema#string

Mark Kunkel

http://www.w3.org/2001/XMLSchema#string

P2860

LOK is a novel mouse STE20-like protein kinase that is expressed predominantly in lymphocytes

LOK is a major ERM kinase in resting lymphocytes and regulates cytoskeletal rearrangement through ERM phosphorylation

The selectivity of protein kinase inhibitors: a further update

Discovery of novel benzimidazoles as potent inhibitors of TIE-2 and VEGFR-2 tyrosine kinase receptors

A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases

Structural Features for Functional Selectivity at Serotonin Receptors

Acetyl-lysine Binding Site of Bromodomain-Containing Protein 4 (BRD4) Interacts with Diverse Kinase Inhibitors

Dual kinase-bromodomain inhibitors for rationally designed polypharmacology

Stereospecific targeting of MTH1 by (S)-crizotinib as an anticancer strategy

Open access chemical and clinical probes to support drug discovery

P2888

P304

95-103

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

2150197

http://www.w3.org/2001/XMLSchema#string

P356

10.1038/NBT.3374

http://www.w3.org/2001/XMLSchema#string

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

34

http://www.w3.org/2001/XMLSchema#string

P50

John P. Overington

Susanne Müller

Jonathan M Elkins

Ayman Al Haj Zen

Francis Atkinson

P577

2016-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

283260001

http://www.w3.org/2001/XMLSchema#string

P6179

1024715377

http://www.w3.org/2001/XMLSchema#string

P698

26501955

http://www.w3.org/2001/XMLSchema#string